Sight Sciences (SGHT) Scheduled to Post Quarterly Earnings on Thursday

Sight Sciences (NASDAQ:SGHT) will be announcing its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Sight Sciences (NASDAQ:SGHT) last posted its earnings results on Thursday, August 1st. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.06. The company had revenue of $21.37 million for the quarter, compared to analyst estimates of $21.32 million. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.90%. During the same period last year, the company earned ($0.30) earnings per share. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sight Sciences Trading Up 0.4 %

Sight Sciences stock opened at $5.29 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.50 and a current ratio of 11.01. The business’s 50-day simple moving average is $6.20 and its 200-day simple moving average is $6.27. The firm has a market capitalization of $266.12 million, a PE ratio of -4.94 and a beta of 2.71. Sight Sciences has a 52 week low of $1.42 and a 52 week high of $8.45.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Morgan Stanley lifted their price objective on Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Lake Street Capital assumed coverage on Sight Sciences in a research note on Wednesday, August 21st. They issued a “buy” rating and a $10.00 price objective on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research note on Friday, August 2nd. Finally, Citigroup lifted their price objective on Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a research note on Wednesday, July 10th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $7.25.

Insider Buying and Selling

In related news, insider Matthew Link sold 21,831 shares of Sight Sciences stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $5.61, for a total transaction of $122,471.91. Following the sale, the insider now directly owns 663,550 shares of the company’s stock, valued at $3,722,515.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Sight Sciences news, insider Jeremy B. Hayden sold 4,878 shares of Sight Sciences stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $6.08, for a total transaction of $29,658.24. Following the sale, the insider now directly owns 158,687 shares of the company’s stock, valued at approximately $964,816.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Matthew Link sold 21,831 shares of Sight Sciences stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $5.61, for a total value of $122,471.91. Following the sale, the insider now directly owns 663,550 shares in the company, valued at $3,722,515.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 97,357 shares of company stock valued at $574,666 over the last three months. 28.90% of the stock is owned by corporate insiders.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.